Literature DB >> 17212639

Risk factors for hepatitis C fibrosis: a prospective study of United States veterans compared with nonveterans.

Z Kayali1, S Tan, L Shinkunas, M Voigt, D R LaBrecque, J T Stapleton, K E Brown, W N Schmidt.   

Abstract

Chronic hepatitis C virus (HCV) infection causes cirrhosis in many infected patients; however, a better understanding of the risk factors for fibrosis progression in high HCV prevalence groups such as US veterans is needed. We wished to compare the demographic, clinical characteristics, and independent variables that influence fibrosis in US veterans vs nonveterans with chronic HCV. HCV-seropositive US veterans (n = 459) and nonveterans (n = 395) prospectively completed a detailed medical, social and occupational questionnaire. Clinical factors for progressive liver disease were compared between veterans and nonveterans and fibrosis stage assessed on liver biopsies (168 veterans and 208 nonveterans). Using polychotomous logistic regression, fibrosis was analysed as both a progressive and categorical outcome to determine independent risk factors for both patient groups. Although veterans were significantly older and had higher lifetime alcohol consumption than nonveterans, their median fibrosis scores did not differ from nonveterans. By univariate analysis, alanine aminotransferase, necroinflammatory activity (NIA), and cryoglobulin positivity were associated with fibrosis in veterans and nonveterans (P < 0.05, all comparisons), whereas steatosis was associated with fibrosis only in nonveterans (P < 0.0001). By multivariate analysis, NIA was an independent risk factor for fibrosis in both groups (P < 0.01). However, fibrosis in nonveterans was also independently associated with steatosis, significant alcohol consumption and age (P < 0.04, all comparisons). Independent risk factors for fibrosis vary among high HCV prevalence groups such as veterans when compared with nonveterans. Understanding specific patient cohort effects is important for determining independent risk factors for disease progression in chronic HCV infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17212639     DOI: 10.1111/j.1365-2893.2006.00764.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  6 in total

1.  Treatment of hepatitis C cryoglobulinemia: mission and challenges.

Authors:  Zeid Kayali; Douglas R Labrecque; Warren N Schmidt
Journal:  Curr Treat Options Gastroenterol       Date:  2006

2.  Effects of a hepatitis C virus educational intervention or a motivational intervention on alcohol use, injection drug use, and sexual risk behaviors among injection drug users.

Authors:  William A Zule; Elizabeth C Costenbader; Curtis M Coomes; Wendee M Wechsberg
Journal:  Am J Public Health       Date:  2009-02-12       Impact factor: 9.308

3.  Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience.

Authors:  Muhammad Idrees; Shazia Rafique; Irshadur Rehman; Haji Akbar; Muhammad-Zubair Yousaf; Sadia Butt; Zunaira Awan; Sobia Manzoor; Madiha Akram; Mahwish Aftab; Bushra Khubaib; Sheikh Riazuddin
Journal:  World J Gastroenterol       Date:  2009-10-28       Impact factor: 5.742

4.  Nonresponse to interferon-α based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis.

Authors:  Myrna L Cozen; James C Ryan; Hui Shen; Robert Lerrigo; Russell M Yee; Edward Sheen; Richard Wu; Alexander Monto
Journal:  PLoS One       Date:  2013-04-25       Impact factor: 3.240

5.  Heme and HO-1 Inhibition of HCV, HBV, and HIV.

Authors:  Warren N Schmidt; M Meleah Mathahs; Zhaowen Zhu
Journal:  Front Pharmacol       Date:  2012-10-04       Impact factor: 5.810

6.  Impact of Cryoglobulinemic Syndrome on the Outcome of Chronic Hepatitis C Virus Infection: A 15-Year Prospective Study.

Authors:  Gianfranco Lauletta; Sabino Russi; Vincenza Conteduca; Loredana Sansonno; Franco Dammacco; Domenico Sansonno
Journal:  Medicine (Baltimore)       Date:  2013-09       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.